MX2007002459A - N-metilhidroxietilamina util en el tratamiento de afecciones del snc. - Google Patents

N-metilhidroxietilamina util en el tratamiento de afecciones del snc.

Info

Publication number
MX2007002459A
MX2007002459A MX2007002459A MX2007002459A MX2007002459A MX 2007002459 A MX2007002459 A MX 2007002459A MX 2007002459 A MX2007002459 A MX 2007002459A MX 2007002459 A MX2007002459 A MX 2007002459A MX 2007002459 A MX2007002459 A MX 2007002459A
Authority
MX
Mexico
Prior art keywords
alkyl
members
aryl
heteroaryl
independently
Prior art date
Application number
MX2007002459A
Other languages
English (en)
Spanish (es)
Inventor
Edward Fox Kleinman
John Charles Murray
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MX2007002459A publication Critical patent/MX2007002459A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
MX2007002459A 2004-09-21 2005-09-09 N-metilhidroxietilamina util en el tratamiento de afecciones del snc. MX2007002459A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61177704P 2004-09-21 2004-09-21
PCT/IB2005/002877 WO2006032999A1 (en) 2004-09-21 2005-09-09 N-methyl hydroxyethylamine useful in treating cns conditions

Publications (1)

Publication Number Publication Date
MX2007002459A true MX2007002459A (es) 2007-05-04

Family

ID=35559297

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007002459A MX2007002459A (es) 2004-09-21 2005-09-09 N-metilhidroxietilamina util en el tratamiento de afecciones del snc.

Country Status (7)

Country Link
US (1) US20080132552A1 (cg-RX-API-DMAC10.html)
EP (1) EP1794114A1 (cg-RX-API-DMAC10.html)
JP (1) JP2008513432A (cg-RX-API-DMAC10.html)
BR (1) BRPI0515528A (cg-RX-API-DMAC10.html)
CA (1) CA2581023A1 (cg-RX-API-DMAC10.html)
MX (1) MX2007002459A (cg-RX-API-DMAC10.html)
WO (1) WO2006032999A1 (cg-RX-API-DMAC10.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2307345A4 (en) * 2008-07-01 2012-05-02 Purdue Research Foundation NON-PEPTIDINHIBITORS OF HIV-1 PROTEASE
US8993572B2 (en) 2010-04-22 2015-03-31 Intra-Cellular Therapies, Inc. Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives
CN102344402B (zh) * 2010-07-30 2015-01-07 中国人民解放军军事医学科学院毒物药物研究所 苯并氮杂环羟乙基胺类化合物、其制备方法和用途
US9428506B2 (en) 2012-04-14 2016-08-30 Intra-Cellular Therapies, Inc. Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders
WO2014145192A1 (en) 2013-03-15 2014-09-18 Intra-Cellular Therapies, Inc. Organic compounds
KR102967223B1 (ko) 2013-12-03 2026-05-19 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
US9745300B2 (en) 2014-04-04 2017-08-29 Intra-Cellular Therapies, Inc. Organic compounds
KR20220054908A (ko) 2014-04-04 2022-05-03 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
RU2743513C2 (ru) 2016-01-26 2021-02-19 Интра-Селлулар Терапиз, Инк. Органические соединения
IL281050B2 (en) 2016-03-25 2023-04-01 Intra Cellular Therapies Inc A controlled or delayed release pharmaceutical preparation containing a deuterated compound
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
JP7013454B2 (ja) 2016-10-12 2022-02-15 イントラ-セルラー・セラピーズ・インコーポレイテッド アモルファス固体分散体
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
EP3562484B1 (en) 2016-12-29 2021-08-25 Intra-Cellular Therapies, Inc. Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders
EP3600325A4 (en) 2017-03-24 2021-01-06 Intra-Cellular Therapies, Inc. UNIQUE COMPOSITIONS AND PROCESSES
JP7224333B2 (ja) 2017-07-26 2023-02-17 イントラ-セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2019023062A1 (en) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
AU2019240226B2 (en) 2018-03-23 2024-11-28 Intra-Cellular Therapies, Inc. Organic compounds
SMT202600133T1 (it) 2018-03-23 2026-05-12 Intra Cellular Therapies Inc Composti organici
EP3801527B1 (en) 2018-06-08 2025-02-19 Intra-Cellular Therapies, Inc. Fused gamma-carbolines for acute treatment of anxiety or depression
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
AU2019328528B2 (en) 2018-08-31 2025-01-23 Intra-Cellular Therapies, Inc. Novel methods
WO2020047408A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
EP4134101A1 (en) 2019-07-07 2023-02-15 Intra-Cellular Therapies, Inc. Deuterated lumateperone for the treatment of the bipolar ii disorder
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2410680A1 (en) 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
AU2002320490B2 (en) 2001-07-11 2008-10-02 Elan Pharmaceuticals, Inc. N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds
GB0228410D0 (en) 2002-12-05 2003-01-08 Glaxo Group Ltd Novel Compounds

Also Published As

Publication number Publication date
US20080132552A1 (en) 2008-06-05
CA2581023A1 (en) 2006-03-30
EP1794114A1 (en) 2007-06-13
JP2008513432A (ja) 2008-05-01
BRPI0515528A (pt) 2008-07-29
WO2006032999A1 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
US20080132552A1 (en) N-methyl hydroxyethylamine useful in treating CNS conditions
US5939449A (en) Substituted 1-phenyl-3-pyrazolecarboxamides active on neurotensin receptors, their preparation and pharmaceutical compositions containing them
AU2019391279B2 (en) Heteroaromatic compounds as Vanin inhibitors
JP4137159B2 (ja) セロトニン及びノルアドレナリン再取り込み阻害薬としてのn−ピロリジン−3−イル−アミド誘導体
US5585497A (en) Substituted 1-naphthyl-3-pyrazolecarboxamides which are active on neurotensin
WO2004110996A1 (en) Nk1 antagonist
DE69507293T2 (de) Benzamid-derivate als vasopressin-antagonisten
JP2016510033A (ja) 強力なrock1およびrock2阻害剤としてのフェニルピラゾール誘導体
JP7195436B2 (ja) バニン阻害剤としての複素芳香族化合物
CA2467749A1 (en) (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
JPH07501071A (ja) 新規エンドセリン拮抗薬およびそれらの製造方法
DE69621877T2 (de) 4-Indolylpiperazinyl-Derivate
JP2011516399A (ja) 新規ぺプチドデホルミラーゼ阻害化合物とその製造方法
JP2009513697A (ja) ヒストンデアセチラーゼの阻害活性を有するアルキルカルバモイルナフタレニルオキシオクテノイルヒドロキシアミド誘導体およびその製造方法
JP2012505241A (ja) アルツハイマー病の治療用組成物
KR20000052921A (ko) 뉴로키닌 길항제로서의 피페라지노 유도체
US20070213368A1 (en) N-ethyl hydroxyethylamine useful in treating cns conditions
CA2567342A1 (en) Aza-bicyclo[3.1.0]hex-1-yl derivatives active as nk1 antagonists
US20090069287A1 (en) Substituted azacycloalkanes useful for treating cns conditions
CN107406461B (zh) 杂环炔烃衍生物及其作为mGluR5受体调节剂的用途
WO2007110727A2 (en) Amide stabilized hydroxyethylamines
AU2008263982A1 (en) Piperazine and [1,4] diazepan derivatives as NK antagonists
JP2005535715A (ja) グリシン作動性を有するr(+)−2−アミノ−3−ヒドロキシプロピオン酸誘導体